CN114948785A - 一种复合小分子活性肽收敛舒缓痤疮红肿次抛精华液 - Google Patents
一种复合小分子活性肽收敛舒缓痤疮红肿次抛精华液 Download PDFInfo
- Publication number
- CN114948785A CN114948785A CN202210421410.8A CN202210421410A CN114948785A CN 114948785 A CN114948785 A CN 114948785A CN 202210421410 A CN202210421410 A CN 202210421410A CN 114948785 A CN114948785 A CN 114948785A
- Authority
- CN
- China
- Prior art keywords
- extract
- active peptide
- parts
- weight
- essence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 45
- -1 Compound small-molecule Chemical class 0.000 title claims abstract description 25
- 238000005498 polishing Methods 0.000 title claims abstract description 19
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 16
- 206010000496 acne Diseases 0.000 title claims abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 139
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 44
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims abstract description 30
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000002131 composite material Substances 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 15
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960001631 carbomer Drugs 0.000 claims abstract description 15
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 13
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 13
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 13
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 11
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 11
- 229940084801 salvia miltiorrhiza root extract Drugs 0.000 claims abstract description 11
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 11
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 11
- 244000144927 Aloe barbadensis Species 0.000 claims abstract description 10
- 235000002961 Aloe barbadensis Nutrition 0.000 claims abstract description 10
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 10
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims abstract description 10
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims abstract description 10
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 10
- 240000006688 Telosma cordata Species 0.000 claims abstract description 10
- 235000017352 Telosma cordata Nutrition 0.000 claims abstract description 10
- 235000020691 dandelion extract Nutrition 0.000 claims abstract description 10
- 229940067866 dandelion extract Drugs 0.000 claims abstract description 10
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 10
- 229930182478 glucoside Natural products 0.000 claims abstract description 10
- 230000008961 swelling Effects 0.000 claims abstract description 10
- 239000001845 taraxacum officinale leaf extract Substances 0.000 claims abstract description 10
- 244000146462 Centella asiatica Species 0.000 claims abstract description 9
- 235000004032 Centella asiatica Nutrition 0.000 claims abstract description 9
- 241000196324 Embryophyta Species 0.000 claims abstract description 9
- 241000767840 Semiaquilegia Species 0.000 claims abstract description 9
- 229940084750 sophora flavescens root extract Drugs 0.000 claims abstract description 9
- 239000000341 volatile oil Substances 0.000 claims abstract description 9
- 244000296102 Selinum monnieri Species 0.000 claims abstract description 7
- 235000019084 Selinum monnieri Nutrition 0.000 claims abstract description 7
- 239000004615 ingredient Substances 0.000 claims abstract description 7
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims abstract description 5
- 229940113115 polyethylene glycol 200 Drugs 0.000 claims abstract description 5
- 102000008186 Collagen Human genes 0.000 claims description 12
- 108010035532 Collagen Proteins 0.000 claims description 12
- 108010038807 Oligopeptides Proteins 0.000 claims description 12
- 102000015636 Oligopeptides Human genes 0.000 claims description 12
- 229920001436 collagen Polymers 0.000 claims description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 244000170916 Paeonia officinalis Species 0.000 claims description 7
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 7
- 241000405414 Rehmannia Species 0.000 claims description 7
- 239000001180 angelica archangelica l. root extract Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 229940119485 safflower extract Drugs 0.000 claims description 7
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 claims description 5
- 108010024636 Glutathione Proteins 0.000 claims description 5
- 241000112528 Ligusticum striatum Species 0.000 claims description 5
- 229960003180 glutathione Drugs 0.000 claims description 5
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 4
- 108010087806 Carnosine Proteins 0.000 claims description 4
- 240000003538 Chamaemelum nobile Species 0.000 claims description 4
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 4
- 241000545744 Hirudinea Species 0.000 claims description 4
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 4
- 229940044199 carnosine Drugs 0.000 claims description 4
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 4
- 239000010628 chamomile oil Substances 0.000 claims description 4
- 239000010634 clove oil Substances 0.000 claims description 4
- 239000010648 geranium oil Substances 0.000 claims description 4
- 235000019717 geranium oil Nutrition 0.000 claims description 4
- 210000001161 mammalian embryo Anatomy 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 3
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 235000019719 rose oil Nutrition 0.000 claims description 3
- 239000010666 rose oil Substances 0.000 claims description 3
- 241000131329 Carabidae Species 0.000 claims description 2
- 241000243684 Lumbricus Species 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000002087 whitening effect Effects 0.000 claims 6
- 239000003814 drug Substances 0.000 abstract description 6
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 206010015150 Erythema Diseases 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 150000003384 small molecules Chemical class 0.000 description 10
- 238000003756 stirring Methods 0.000 description 6
- 241000212948 Cnidium Species 0.000 description 5
- 240000007049 Juglans regia Species 0.000 description 5
- 235000009496 Juglans regia Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000020234 walnut Nutrition 0.000 description 5
- 241000167550 Centella Species 0.000 description 4
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 4
- 229940093767 glabridin Drugs 0.000 description 4
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 4
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N Histidine Chemical compound OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N THREONINE Chemical compound CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 2
- ZGSCRDSBTNQPMS-UJURSFKZSA-N 3-O-Ethylascorbic acid Chemical compound CCOC1=C(O)C(=O)O[C@@H]1[C@@H](O)CO ZGSCRDSBTNQPMS-UJURSFKZSA-N 0.000 description 2
- 229940120145 3-o-ethylascorbic acid Drugs 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000361919 Metaphire sieboldi Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 229940114124 ferulic acid Drugs 0.000 description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 2
- 235000001785 ferulic acid Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 241000208836 Adoxa moschatellina Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241001489978 Eupolyphaga Species 0.000 description 1
- 241000694589 Gesneria viridiflora Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000009188 angelicae sinensis extract Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 235000005770 birds nest Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 235000005765 wild carrot Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及一种易于吸收的复合小分子活性肽收敛舒缓痤疮红肿次抛精华液，由复合小分子活性肽、甘油、卡波姆、EDTA二钠、三乙醇胺、1,3‑丙二醇、聚乙二醇‑200、改良桃红四物汤提取物、凝血酸、库拉索芦荟胶、水杨酸、甘草酸二钾、麦芽寡糖葡糖苷、苦参根提取物、积雪草花/叶/茎提取物、蛇床果提取物、丹参根提取物、忍冬花提取物、野菊花提取物、蒲公英提取物、紫花地丁提取物、天葵子提取物、植物精油、水等成分组成。含有中药传统方剂桃红四物汤，可以缓解粉刺、痤疮、闭口等肌肤红肿问题，活化、促进细胞恢复正常，同时搭配多种中药提取物及其他小分子成分，让皮肤能保持更好的状态。
Description
技术领域
本发明属于化妆品技术领域，具体涉及一种复合小分子活性肽收敛舒缓痤疮红肿次抛精华液。
背景技术
由于生活环境的变化、日常护理品的广泛使用以及涂抹化妆类产品的过度使用，导致消费者的皮肤变得越来越脆弱敏感，致使皮肤角质层过度角质化的问题不断出现。现在的人们由于工作生活压力增加、周围扬尘机动车尾气等环境污染、大气气候变暖阳光紫外线增强，再加上现在的外卖食品添加剂使用过多，消费者上餐下餐饮食不规律，饮食偏油腻，熬夜多作息不规律等种种原因综合，影响到了皮肤，让身体及皮肤处于一种极度不平衡的状态，很容易就出现痤疮、闭口、痘痘等情况，特别是紫外线，生活、工作的各种压力的影响，更是对这种情况加深。
内部功能的缺乏，我们要从外部进行补救，而精华液含有活化、促进细胞恢复正常等作用，所以，用好精华液，就能让肌肤保持更好的状态。
市场常见的水、乳液、面霜中的营养分子因为成分分子量相对较大，吸收效果和渗透能力十分有限，难以达到较好的护肤效果。且大多数精华液为30-300ml的包装，一旦开封使用后很难保证不被污染，平时只能放在家中，出差等携带不方便。而“次抛”即“一次一抛”，采用“吹(Blow)、灌(Fill)、封(Seal)”(BFS)自动化无菌一体成型技术，保证使用时不被污染，次抛精华液一般1-1.5ml每独立包装，体积小，携带方便，综上，次抛精华液较传统精华液，既提高了消费者使用的携带性方便性，又能保证使用时的安全性。
发明内容
本发明的目的是提供一种易于吸收的复合小分子活性肽收敛舒缓痤疮红肿次抛精华液，本发明主要采用以下技术方案：
本发明的一种小分子活性肽精华液包含以下原料：复合小分子活性肽、甘油、卡波姆、EDTA二钠、三乙醇胺、1,3-丙二醇、聚乙二醇-200、改良桃红四物汤提取物、凝血酸、库拉索芦荟胶、水杨酸、甘草酸二钾、麦芽寡糖葡糖苷、苦参根提取物、积雪草花/叶/茎提取物、蛇床果提取物、丹参根提取物、忍冬花提取物、野菊花提取物、蒲公英提取物、紫花地丁提取物、天葵子提取物、植物精油、水。
进一步的，原料的重量配比为：复合小分子活性肽1～10重量份、甘油2～10重量份、卡波姆1～5重量份、EDTA二钠1～5重量份、三乙醇胺1～5重量份、1,3-丙二醇1～10重量份、聚乙二醇-200 0.1～1重量份、改良桃红四物汤提取物0.6～6重量份、凝血酸0.1～1重量份、库拉索芦荟胶0.1～1重量份、水杨酸0.1～1重量份、甘草酸二钾0.1～1重量份、麦芽寡糖葡糖苷0.1～1重量份、苦参根提取物0.1～1重量份、积雪草花/叶/茎提取物0.1～1重量份、蛇床果提取物0.1～1重量份、丹参根提取物0.1～1重量份、忍冬花提取物0.1～1重量份、野菊花提取物0.1～1重量份、蒲公英提取物0.1～1重量份、紫花地丁提取物0.1～1重量份、天葵子提取物0.1～1重量份、植物精油0.001～0.1重量份、水38～90重量份。
本发明所用到的改良桃红四物汤提取物是由红花提取物、桃核仁提取物、川芎提取物、当归根提取物、地黄根提取物、芍药根提取物按照1:1:1:1:1:1的重量比组成，依据于中医传统经典名方-桃红四物汤，该组分含有的有效成分为阿魏酸等水溶性小分子物质。
本发明所用到的复合小分子活性肽是由以下组合中的任一种组成的：
组成1：寡肽-1、九肽-1、水解胶原、蛭提取物、参环毛蚓提取物、胚胎提取物按照1:0.05:0.25:0.25:0.25:0.25的重量比组成，其中含有有效的肽链结构为VCERA。
组成2：谷胱甘肽、天龙寡肽、土鳖虫寡肽、水解胶原、寡肽-1按照1:0.2:0.2:0.5:0.8的重量比组成，其中含有有效的肽链结构为TVFIK。
组成3：水解胶原、寡肽-6、土鳖虫寡肽、肌肽、四肽-1按照1:0.5:0.2:0.5:0.3的重量比组成，其中含有有效的肽链结构为ALTAGL。
其中有效的肽链结构VCERA、TVFIK、ALTAGL，该结构表述为氨基酸的排列顺序，字母为氨基酸的英文缩写，各字母代表如下：丙氨酸,Ala,A，缬氨酸,Val,V，亮氨酸,Leu,L，异亮氨酸,Ile,I，甲硫氨酸,Met,M，脯氨酸,Pro,P，苯丙氨酸,Phe,F，色氨酸，Trp,W，丝氨酸,Ser,S，苏氨酸,Thr,T，酪氨酸,Tyr,Y，半胱氨酸,Cys,C，天冬酰胺,Asn,N，谷氨酰胺,Gln,Q，甘氨酸,Gly,G，天冬氨酸,Asp,D，谷氨酸,Glu,E，赖氨酸,Lys,K，精氨酸,Arg,R，组氨酸,His,H。
本发明所用到的复合小分子活性肽，分子量均小于1500D，通过组合配比，提供了多成分、多营养的透皮物质基础及溶栓溶斑活性成分。所用到的红花提取物、桃核仁提取物、川芎提取物、当归根提取物、地黄根提取物、芍药根提取物，该6种提取物配伍组合使用，依据于中医传统经典名方-桃红四物汤的处方改良而来，桃红四物汤临床使用悠久，具有明确的养血、活血、逐淤功效，其中含有的阿魏酸等水溶性小分子物质，具有良好的抗氧化作用；该组合应用于护肤品精华液中具有创新性。
《中国药典》2020年版中记载，桃仁性苦、甘，平。归心、肝、大肠经。具有活血祛瘀，润肠通便，止咳平喘的功能。用于经闭痛经，癥瘕痞块，肺痈肠痈，跌扑损伤，肠燥便秘，咳嗽气喘。核桃仁性甘，温。归肾、肺、大肠经。具有补肾，温肺，润肠的功能。用于肾阳不足，腰膝酸软，阳痿遗精，虚寒喘嗽，肠燥便秘。本发明中通过对桃红四物汤原方的改良，以核桃仁代替桃仁，取其共同的性甘、归大肠经，以及润肠的功能。众所周知，很多时候肤色暗沉发黄跟体内毒素、垃圾过多有关系，通过润肠通便的成分来助于促进肠胃蠕动排出体内的毒素，毒素清理出去了，皮肤分次、痤疮、闭口等问题就会迎刃而解。这也是本发明的独创性的特点之一。
本发明中的植物精油为玫瑰花油、薰衣草油、丁香油、罗马洋甘菊油、天竺葵油中的任意一种或多种组成。
本发明精华液的制备方法为：
(1)将卡波姆加入水中，室温润胀24～48小时。
(2)将EDTA二钠、红花提取物、桃核仁提取物、川芎提取物、当归根提取物、地黄根提取物、芍药根提取物、凝血酸、库拉索芦荟胶、水杨酸、甘草酸二钾、麦芽寡糖葡糖苷、苦参根提取物、积雪草花/叶/茎提取物、蛇床果提取物、丹参根提取物、忍冬花提取物、野菊花提取物、蒲公英提取物、紫花地丁提取物、天葵子提取物加入水中，加热至50±5℃溶解，搅拌均匀，待混合药液冷却至室温，备用。
(3)将植物精油、甘油、1,3-丙二醇、聚乙二醇-200混合，搅拌均匀，备用。
(4)将(2)、(3)依次加入至(1)中，加入三乙醇胺，搅拌均匀，加或不加防腐剂，微孔滤膜滤过灭菌，即得。
本发明中防腐剂为羟苯甲酯、苯氧乙醇。
本发明精华液的使用方法为：每天早晚，于爽肤水后，精华乳和面霜之前使用。本品具有良好的延展性，只需3滴，就可以均匀涂抹脸部。
本发明精华液中含有多种小分子活性肽成分，能够持久保湿，减轻粉刺、痤疮、闭口等红肿问题，令肌肤得到舒缓，恢复正常健康状态。
本发明精华液能够轻松通过角质层，进入表皮，再渗入基底被基底细胞所吸收，从根部护肤。该精华液通过多种功效原料的组合配比，可以很好的解决肌肤痤疮的问题，使得规律使用本精华液的皮肤能恢复健康红润莹亮的状态。
为进一步考察本发明精华液的质量，分别制备8份不同样品，招募公司员工及亲属30人(女性26人，男性4人)进行自愿、免费试用，实验如下：
(1)实验样品
样品1：实施例1的精华液。
样品2：实施例2的精华液。
样品3：实施例3的精华液。
样品4：复合小分子活性肽(寡肽-1、九肽-1按照1:1的重量比组成)10重量份、甘油3重量份、卡波姆2重量份、EDTA二钠2重量份、三乙醇胺1重量份、1,3-丙二醇1重量份、聚乙二醇-200 0.2重量份、红花提取物0.5重量份、桃核仁提取物0.5重量份、川芎提取物0.5重量份、当归根提取物0.5重量份、地黄根提取物0.5重量份、芍药根提取物0.5重量份、凝血酸0.5重量份、库拉索芦荟胶0.5重量份、水杨酸0.5重量份、甘草酸二钾0.5重量份、麦芽寡糖葡糖苷0.5重量份、苦参根提取物0.5重量份、积雪草花/叶/茎提取物0.5重量份、蛇床果提取物0.5重量份、丹参根提取物0.5重量份、丁香油0.1重量份、水65.9重量份。(每重量份10g)
样品5：复合小分子活性肽(九肽-1、酵母多肽、水解胶原、蛭提取物、参环毛蚓提取物、胚胎提取物按照1:0.05:0.25:0.25:0.25:0.25的重量比组成)5重量份、甘油3重量份、卡波姆2重量份、EDTA二钠2重量份、三乙醇胺1重量份、1,3-丙二醇1重量份、聚乙二醇-2000.2重量份、苦参根提取物0.5重量份、丹参根提取物0.5重量份、蛇床果提取物0.5重量份、积雪草花/叶/茎提取物1重量份、烟酰胺2重量份、光甘草定0.2重量份、燕窝提取物0.5重量份、天竺葵油0.1重量份、水80重量份。(每重量份50g)
样品6：复合小分子活性肽(谷胱甘肽、天龙寡肽、土鳖虫寡肽、水解胶原、寡肽-1按照1:0.2:0.2:0.5:0.8的重量比组成)10重量份、甘油3重量份、卡波姆2重量份、EDTA二钠2重量份、三乙醇胺1重量份、1,3-丙二醇1重量份、聚乙二醇-200 0.2重量份、忍冬花提取物0.5重量份、野菊花提取物0.5重量份、蒲公英提取物0.5重量份、紫花地丁1重量份、天葵子提取物2重量份、光甘草定0.2重量份、燕窝提取物0.5重量份、罗马洋甘菊油0.1重量份、水75.5重量份。(每重量份10g)
样品7：复合小分子活性肽(水解胶原、寡肽-6、土鳖虫寡肽、肌肽、四肽-1按照1:0.5:0.2:0.5:0.3的重量比组成)10重量份、甘油3重量份、卡波姆2重量份、EDTA二钠2重量份、三乙醇胺1重量份、1,3-丙二醇1重量份、聚乙二醇-200 0.2重量份、苦参根提取物0.5重量份、丹参根提取物0.5重量份、蛇床果提取物0.5重量份、积雪草花/叶/茎提取物1重量份、烟酰胺2重量份、光甘草定0.2重量份、3-邻-乙基抗坏血酸2重量份、熊果苷2重量份、燕窝提取物0.5重量份、丁香油0.1重量份、水71.5重量份。(每重量份50g)
样品8：谷胱甘肽5重量份、甘油3重量份、卡波姆2重量份、EDTA二钠2重量份、三乙醇胺1重量份、1,3-丙二醇1重量份、聚乙二醇-200 0.2重量份、苦参根提取物0.5重量份、丹参根提取物0.5重量份、蛇床果提取物0.5重量份、积雪草花/叶/茎提取物1重量份、烟酰胺2重量份、光甘草定0.2重量份、3-邻-乙基抗坏血酸2重量份、熊果苷2重量份、燕窝提取物0.5重量份、天竺葵油0.1重量份、水76.5重量份。(每重量份10g)
(2)实验方法
分别对8份样品进行试用60天观察，从减轻舒缓痤疮、粉刺红肿(3分)、保持湿润(2分)、提升弹性(3分)、气味芳香(1分)、延展性(1分)五个方面体验，求得各样品评价得分，结果如下：
| 样品编号 | 评价得分 |
| 样品1 | 96 |
| 样品2 | 94 |
| 样品3 | 91 |
| 样品4 | 88 |
| 样品5 | 84 |
| 样品6 | 80 |
| 样品7 | 81 |
| 样品8 | 78 |
结果可见，本发明产品(样品1、样品2、样品3)的评价得分较高。尤其在于不同复合小分子活性肽的原料组成、不同配比所导致的效果差异明显，本发明配方的原料组成及配比具有显著的效果。
具体实施方式
面结合实施例对本发明进行更进一步详细说明，但不是对本发明的限定。
实施例1
一种复合小分子活性肽精华液，原辅料组成为：复合小分子活性肽(寡肽-1、九肽-1、水解胶原、蛭提取物、参环毛蚓提取物、胚胎提取物按照1:0.05:0.25:0.25:0.25:0.25的重量比组成)10重量份、甘油3重量份、卡波姆2重量份、EDTA二钠2重量份、三乙醇胺1重量份、1,3-丙二醇1重量份、聚乙二醇-200 0.2重量份、红花提取物0.5重量份、桃核仁提取物0.5重量份、川芎提取物0.5重量份、当归根提取物0.5重量份、地黄根提取物0.5重量份、芍药根提取物0.5重量份、凝血酸0.5重量份、库拉索芦荟胶0.5重量份、水杨酸0.5重量份、甘草酸二钾0.5重量份、麦芽寡糖葡糖苷0.5重量份、苦参根提取物0.5重量份、积雪草花/叶/茎提取物0.5重量份、蛇床果提取物0.5重量份、丹参根提取物0.5重量份、忍冬花提取物0.5重量份、野菊花提取物0.5重量份、蒲公英提取物0.5重量份、紫花地丁提取物0.5重量份、天葵子提取物0.5重量份、玫瑰花油0.1重量份、水70.7重量份。(每重量份100g)
实施例2
一种复合小分子活性肽精华液，原辅料组成为：复合小分子活性肽(谷胱甘肽、天龙寡肽、土鳖虫寡肽、水解胶原、寡肽-1按照1:0.2:0.2:0.5:0.8的重量比组成)1重量份、甘油3重量份、卡波姆2重量份、EDTA二钠2重量份、三乙醇胺1重量份、1,3-丙二醇1重量份、聚乙二醇-200 0.2重量份、红花提取物0.5重量份、桃核仁提取物0.5重量份、川芎提取物0.5重量份、当归根提取物0.5重量份、地黄根提取物0.5重量份、芍药根提取物0.5重量份、凝血酸0.5重量份、库拉索芦荟胶0.5重量份、水杨酸0.5重量份、甘草酸二钾0.5重量份、麦芽寡糖葡糖苷0.5重量份、苦参根提取物0.5重量份、积雪草花/叶/茎提取物0.5重量份、蛇床果提取物0.5重量份、丹参根提取物0.5重量份、忍冬花提取物0.5重量份、野菊花提取物0.5重量份、蒲公英提取物0.5重量份、紫花地丁提取物0.5重量份、天葵子提取物0.5重量份、薰衣草油0.1重量份、水79.7重量份。(每重量份100g)
实施例3
一种复合小分子活性肽精华液，原辅料组成为：复合小分子活性肽(水解胶原、寡肽-6、土鳖虫寡肽、肌肽、四肽-1按照1:0.5:0.2:0.5:0.3的重量比组成)5重量份、甘油3重量份、卡波姆2重量份、EDTA二钠2重量份、三乙醇胺1重量份、1,3-丙二醇1重量份、聚乙二醇-200 0.2重量份、红花提取物0.5重量份、桃核仁提取物0.5重量份、川芎提取物0.5重量份、当归根提取物0.5重量份、地黄根提取物0.5重量份、芍药根提取物0.5重量份、凝血酸0.5重量份、库拉索芦荟胶0.5重量份、水杨酸0.5重量份、甘草酸二钾0.5重量份、麦芽寡糖葡糖苷0.5重量份、苦参根提取物0.5重量份、积雪草花/叶/茎提取物0.5重量份、蛇床果提取物0.5重量份、丹参根提取物0.5重量份、忍冬花提取物0.5重量份、野菊花提取物0.5重量份、蒲公英提取物0.5重量份、紫花地丁提取物0.5重量份、天葵子提取物0.5重量份、罗马洋甘菊油0.1重量份、水75.7重量份。(每重量份10g)
制备方法为：
(1)将卡波姆加入水中，室温润胀24～48小时。
(2)将EDTA二钠、红花提取物、桃核仁提取物、川芎提取物、当归根提取物、地黄根提取物、芍药根提取物、凝血酸、库拉索芦荟胶、水杨酸、甘草酸二钾、麦芽寡糖葡糖苷、苦参根提取物、积雪草花/叶/茎提取物、蛇床果提取物、丹参根提取物、忍冬花提取物、野菊花提取物、蒲公英提取物、紫花地丁提取物、天葵子提取物加入水中，加热至50±5℃溶解，搅拌均匀，待混合药液冷却至室温，备用。
(3)将植物精油、甘油、1,3-丙二醇、聚乙二醇-200混合，搅拌均匀，备用。
(4)将(2)、(3)依次加入至(1)中，加入三乙醇胺，搅拌均匀，微孔滤膜滤过灭菌，即得。
Claims (8)
1.一种复合小分子活性肽收敛舒缓痤疮红肿次抛精华液，其特征在于所述精华液包含以下原料：复合小分子活性肽、甘油、卡波姆、EDTA二钠、三乙醇胺、1,3-丙二醇、聚乙二醇-200、改良桃红四物汤提取物、凝血酸、库拉索芦荟胶、水杨酸、甘草酸二钾、麦芽寡糖葡糖苷、苦参根提取物、积雪草花/叶/茎提取物、蛇床果提取物、丹参根提取物、忍冬花提取物、野菊花提取物、蒲公英提取物、紫花地丁提取物、天葵子提取物、植物精油、水。
2.如权利要求1所述的复合小分子活性肽美白次抛精华液，其特征在于所述精华液包含以下原料：复合小分子活性肽1～10重量份、甘油2～10重量份、卡波姆1～5重量份、EDTA二钠1～5重量份、三乙醇胺1～5重量份、1,3-丙二醇1～10重量份、聚乙二醇-2000.1～1重量份、改良桃红四物汤提取物0.6～6重量份、凝血酸0.1～1重量份、库拉索芦荟胶0.1～1重量份、水杨酸0.1～1重量份、甘草酸二钾0.1～1重量份、麦芽寡糖葡糖苷0.1～1重量份、苦参根提取物0.1～1重量份、积雪草花/叶/茎提取物0.1～1重量份、蛇床果提取物0.1～1重量份、丹参根提取物0.1～1重量份、忍冬花提取物0.1～1重量份、野菊花提取物0.1～1重量份、蒲公英提取物0.1～1重量份、紫花地丁提取物0.1～1重量份、天葵子提取物0.1～1重量份、植物精油0.001～0.1重量份、水38～90重量份。
3.如权利要求1或2所述的复合小分子活性肽美白次抛精华液，其特征在于所述的改良桃红四物汤提取物是由红花提取物、桃核仁提取物、川芎提取物、当归根提取物、地黄根提取物、芍药根提取物按照1:1:1:1:1:1的重量比组成。
4.如权利要求1或2所述的复合小分子活性肽美白次抛精华液，其特征在于所述的复合小分子活性肽是由寡肽-1、九肽-1、水解胶原、蛭提取物、参环毛蚓提取物、胚胎提取物按照1:0.05:0.25:0.25:0.25:0.25的重量比组成，其中含有有效的肽链结构为VCERA。
5.如权利要求1或2所述的复合小分子活性肽美白次抛精华液，其特征在于所述的复合小分子活性肽是由谷胱甘肽、天龙寡肽、土鳖虫寡肽、水解胶原、寡肽-1按照1:0.2:0.2:0.5:0.8的重量比组成，其中含有有效的肽链结构为TVFIK。
6.如权利要求1或2所述的复合小分子活性肽美白次抛精华液，其特征在于所述的复合小分子活性肽是由水解胶原、寡肽-6、土鳖虫寡肽、肌肽、四肽-1按照1:0.5:0.2:0.5:0.3的重量比组成，其中含有有效的肽链结构为ALTAGL。
7.如权利要求1或2所述的复合小分子活性肽美白次抛精华液，其特征在于所述的植物精油为玫瑰花油、薰衣草油、丁香油、罗马洋甘菊油、天竺葵油中的任意一种或多种组成。
8.如权利要求1或2所述的复合小分子活性肽收敛舒缓痤疮红肿次抛精华液，其特征在于该精华液在制备用于改善肌肤粉刺、痤疮、闭口等红肿问题的化妆品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210421410.8A CN114948785A (zh) | 2022-04-21 | 2022-04-21 | 一种复合小分子活性肽收敛舒缓痤疮红肿次抛精华液 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210421410.8A CN114948785A (zh) | 2022-04-21 | 2022-04-21 | 一种复合小分子活性肽收敛舒缓痤疮红肿次抛精华液 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114948785A true CN114948785A (zh) | 2022-08-30 |
Family
ID=82978160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210421410.8A Pending CN114948785A (zh) | 2022-04-21 | 2022-04-21 | 一种复合小分子活性肽收敛舒缓痤疮红肿次抛精华液 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114948785A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104055685A (zh) * | 2014-06-22 | 2014-09-24 | 广州悠美生物科技有限责任公司 | 一种生物活性小分子多肽角蛋白精华液 |
| CN110063911A (zh) * | 2019-06-11 | 2019-07-30 | 包磊 | 一种复合小分子活性肽精华液 |
-
2022
- 2022-04-21 CN CN202210421410.8A patent/CN114948785A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104055685A (zh) * | 2014-06-22 | 2014-09-24 | 广州悠美生物科技有限责任公司 | 一种生物活性小分子多肽角蛋白精华液 |
| CN110063911A (zh) * | 2019-06-11 | 2019-07-30 | 包磊 | 一种复合小分子活性肽精华液 |
Non-Patent Citations (1)
| Title |
|---|
| 丁兆平: "《发现本草之旅2》", 中国医药科技出版社, pages: 358 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103906526B (zh) | 利用药用花的包裹发酵方法及利用其的皮肤外用剂组合物 | |
| CN100569088C (zh) | 一种清润型凉茶及其制作方法 | |
| JP3415197B2 (ja) | 皮膚外用剤 | |
| CN105997836A (zh) | 一种酵素洗发水及其配制方法 | |
| CN104906028B (zh) | 一种具有改善皮肤问题的发酵物组合物及其应用 | |
| CN104784507A (zh) | 一种具有多重美容功效的中药组合物及其制备方法和应用 | |
| CN111714425B (zh) | 用于改善头皮及头发状态的洗发剂组合物 | |
| CN108938493A (zh) | 一种中药组合物及其制备方法和应用 | |
| CN110522695A (zh) | 一种私处洁肤浴盐及制备方法和应用 | |
| CN106359720A (zh) | 一种清咽利喉和润肺清火的保健茶及其制备方法 | |
| CN106377474A (zh) | 一种铁皮石斛面膜及其制作方法 | |
| CN106309911B (zh) | 抗衰老中药组合物及其制备方法 | |
| CN104887602A (zh) | 茉莉洗头洗面液 | |
| CN109010220B (zh) | 一种化妆品组合物及其制备方法 | |
| CN114948785A (zh) | 一种复合小分子活性肽收敛舒缓痤疮红肿次抛精华液 | |
| KR20090020234A (ko) | 생약 추출물과 생약 분말을 함유하는 한방 화장료 조성물 | |
| CN105342966A (zh) | 含有日本医蛭的护肤保湿霜及其制备方法 | |
| KR102451720B1 (ko) | 피부진정, 피지억제, 가려움 완화 또는 피부보습 효과를 갖는 황금, 로즈마리, 어성초, 사철쑥 및 카렌둘라의 추출물을 함유하는 복합 기능성 조성물을 포함하는 화장료 조성물 및 그 제조 방법 | |
| CN115054564A (zh) | 一种复合小分子活性肽美白次抛精华液 | |
| CN115054532A (zh) | 一种复合小分子活性肽保湿次抛精华液 | |
| CN106943313A (zh) | 一种具有抗衰老功效的中药复方精油及其制备方法 | |
| CN102641231B (zh) | 中药十二白润肤霜及其制备方法 | |
| CN105147531A (zh) | 一种防晒霜及其制备方法 | |
| CN105106085A (zh) | 凹凸棒中草药防晒霜 | |
| KR100512929B1 (ko) | 녹두분, 지각 또는 당귀의 한약재를 함유한 목욕용 조성물및 이를 이용한 목욕제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220830 |